Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0RSBMJ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Sofituzumab vedotin
|
|||||
| Synonyms |
sofituzumab vedotin; RG7458; DMUC5754A; 3A5-MMAE
Click to Show/Hide
|
|||||
| Organization |
Roche (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
~4.3
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Sofituzumab
|
Antibody Info | ||||
| Antigen Name |
Mucin-16 (MUC16)
|
Antigen Info | ||||
| Payload Name |
MMAE
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
vedotin
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic cancer |
1 Trials
|
||||||||
| Ovarian cancer |
1 Trials
|
General Information of The ADMET Data Related to This ADC(2027 Update)
Absorption
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) | 6.65 | ug/mL |
DMUC5754A pharmacokinetics summary, 0.3 mg/kg, Cancer Type-OC, n=3.
|
[1] |
| Maximum Observed Concentration (Cmax) | 16.6 | ug/mL |
DMUC5754A pharmacokinetics summary, 0.6 mg/kg, Cancer Type-OC, n=3.
|
[1] |
| Maximum Observed Concentration (Cmax) | 22.5 | ug/mL |
DMUC5754A pharmacokinetics summary, 1.2 mg/kg, Cancer Type-OC, n=3.
|
[1] |
| Maximum Observed Concentration (Cmax) | 35.5 | ug/mL |
DMUC5754A pharmacokinetics summary, 1.8 mg/kg, Cancer Type-OC, n=3.
|
[1] |
| Maximum Observed Concentration (Cmax) | 42.2 | ug/mL |
DMUC5754A pharmacokinetics summary, 2.4 mg/kg, Cancer Type-OC, n=29.
|
[1] |
| Maximum Observed Concentration (Cmax) | 38.9 | ug/mL |
DMUC5754A pharmacokinetics summary, 2.4 mg/kg, Cancer Type-PC, n=10.
|
[1] |
| Maximum Observed Concentration (Cmax) | 71.4 | ug/mL |
DMUC5754A pharmacokinetics summary, 3.2 mg/kg, Cancer Type-OC, n=3.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 13.1 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 0.3 mg/kg, Cancer Type-OC, n=3.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 29.5 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 0.6 mg/kg, Cancer Type-OC, n=3.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 81.8 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 1.2 mg/kg, Cancer Type-OC, n=3.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 106 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 1.8 mg/kg, Cancer Type-OC, n=3.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 178 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 2.4 mg/kg, Cancer Type-OC, n=29.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 167 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 2.4 mg/kg, Cancer Type-PC, n=10.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 324 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 3.2 mg/kg, Cancer Type-OC, n=3.
|
[1] |
Distribution
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 13.1 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 0.3 mg/kg, Cancer Type-OC, n=3.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 29.5 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 0.6 mg/kg, Cancer Type-OC, n=3.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 81.8 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 1.2 mg/kg, Cancer Type-OC, n=3.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 106 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 1.8 mg/kg, Cancer Type-OC, n=3.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 178 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 2.4 mg/kg, Cancer Type-OC, n=29.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 167 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 2.4 mg/kg, Cancer Type-PC, n=10.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 324 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 3.2 mg/kg, Cancer Type-OC, n=3.
|
[1] |
Metabolism
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 13.1 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 0.3 mg/kg, Cancer Type-OC, n=3.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 29.5 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 0.6 mg/kg, Cancer Type-OC, n=3.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 81.8 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 1.2 mg/kg, Cancer Type-OC, n=3.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 106 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 1.8 mg/kg, Cancer Type-OC, n=3.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 178 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 2.4 mg/kg, Cancer Type-OC, n=29.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 167 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 2.4 mg/kg, Cancer Type-PC, n=10.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 324 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 3.2 mg/kg, Cancer Type-OC, n=3.
|
[1] |
Excretion
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 13.1 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 0.3 mg/kg, Cancer Type-OC, n=3.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 29.5 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 0.6 mg/kg, Cancer Type-OC, n=3.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 81.8 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 1.2 mg/kg, Cancer Type-OC, n=3.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 106 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 1.8 mg/kg, Cancer Type-OC, n=3.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 178 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 2.4 mg/kg, Cancer Type-OC, n=29.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 167 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 2.4 mg/kg, Cancer Type-PC, n=10.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 324 | ug*h/mL |
DMUC5754A pharmacokinetics summary, AUCinf. 3.2 mg/kg, Cancer Type-OC, n=3.
|
[1] |
References